CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 83 enrolled
Drug / intervention
RNS60 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04693715
NCT04693715Phase 2Completed
CompareCT.gov

RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

Revalesio Corporation·interventional·Posted Jan 5, 2021·Updated Jan 12, 2026

In Brief

A Phase 2 clinical trial evaluating RNS60 and Placebo for Stroke, Ischemic. Completed, enrolled 83 participants across 7 sites.

Detailed Summary

A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular revascularization. Participants will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up to a maximum of 65 mL/h), 1.0 mL/kg/h RNS60 (up to a maximum of 130 mL/h), or 1.0 mL/kg/h (up to a maximum of 130 mL/h) placebo (normal saline) starting within 30 minutes of consent after confirmation of candidacy for endovascular thrombectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Ischemic
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJan 5, 2021
Enrollment StartJul 7, 2021
Primary CompletionNov 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.5 years ago

Interventions

RNS60drug

RNS60 injection solution

Placebodrug

Placebo injection solution